Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model

AAPS Journal

Volumn 6, Issue 3, 2004, Pages

  Elzainy, Abeer A W ^a   Gu, Xiaochen ^a   Simons, F Estelle R ^b   Simons, Keith J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antihistamine; Cetirizine; L phosphatidylcholine hydrogenated; Liposomes; Rabbit skin

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; HISTAMINE; LIPOSOME; PHOSPHATIDYLCHOLINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HYDROGENATION; NONHUMAN; RABBIT; RANDOMIZATION; SEDATION; SKIN ABSORPTION; SKIN ALLERGY; SKIN TEST; TIME; ABSORPTION; ANIMAL; TOPICAL DRUG ADMINISTRATION;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; CETIRIZINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; LIPOSOMES; MODELS, ANIMAL; PHOSPHATIDYLCHOLINES; RABBITS;

EID: 33646637673     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj060318     Document Type: Article

References (27)

1. 1-Antihistamines in Allergic Disease. New York, NY: Marcel Dekker Inc; 2002:100-139.
2. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs. 2001;61:2231-2240.
3. Meltzer EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:455-463.
4. Canonica GW, Ciprandi G. Minimal persistent inflammation may be controlled by cetirizine. Ann Allergy Asthma Immunol. 1999;83:445-448.
5. 1-Antihistamines in Allergic Disease. New York, NY: Marcel Dekker Inc; 2002:437-464.
6. 1-antihistamines: example of cetirizine. Ann Allergy Asthma Immunol. 1999;83:489-491.
7. Unger E, Fritz T, Shen DK, Wu G. Manganese-based liposomes: comparative approach. Invest Radiol. 1993;28:933-938.
8. Antonov VF, Anosov AA, Norik VP, Korepanova EA, Smirnova EY. Electrical capacitance of lipid bilayer membranes of hydrogenated egg lecithin at the temperature phase transition. Eur Biophys J. 2003;32:55-59.
9. Williams AC. Transdermal and Topical Drug Delivery. London, UK: Pharmaceutical Press; 2003.
10. El-Ridy MS, Khalil RM. Free versus liposome-encapsulated lignocaine hydrochloride topical applications. Pharmazie. 1999;54:682-684.
11. Yarosh DB. Topical application of liposomes. J Photochem Photobiol B. 1990;6:445-449. DOI
12. United States Pharmacopeial Convention. USP 22-NF 17. Rockville, MD: United States Pharmacopeial Convention Inc; 1990:1785.
13. Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190:63-71. DOI
14. Simons KJ, Elzainy AAW, Gu X, Simons FER. Effect of different phospholipids on the stability of liposomal formulations containing cetirizine [abstract]. AAPS PharmSci. 2003; 5(S1):Abstract T3272. Available at: http://www.aapspharmsci.org/. Accessed January 9, 2004.
15. Elzainy AAW, Gu X, Simons FER, Simons KJ. Evaluation of peripheral antihistaminic activity and systemic absorption of cetirizine from various topical phospholipids liposomal formulations in a rabbit model [abstract]. AAPS PharmSci. 2002;4(S1):Abstract T3256. Available at: http://www.aapspharmsci.org/. Accessed January 9, 2004.
16. 1-receptor antagonists in the skin and serum. J Allergy Clin Immunol. 1995;95:759-764.
17. 111In. Biochim Biophys Acta. 1993;1150:162-164. DOI
18. Bhalerao SS, Harshal AR. Preparation, optimization, characterization, and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm. 2003;29:451-467. DOI
19. Balen GPV, Caron G, Ermondi G, et al. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res. 2001;18:694-701. DOI
20. Watson WTA, Simons KJ, Chen XY, Simons FER. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:457-464.
21. Nielsen PN, Skov PS, Poulsen LK, Schmelz M, Petersen LJ. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy. 2001;31:1378-1384. DOI
22. Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J Microencapsul. 1990;7:479-489.
23. Egbaria K, Ramachandran C, Weiner N. Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin. Skin Pharmacol. 1990;3:21-28.
24. Egbaria K, Ramachandran C, Weiner N. Topical application of liposomally entrapped ciclosporin evaluated by in vitro diffusion studies with human skin. Skin Pharmacol. 1991;4:21-28.
25. Fisher R, Murphy M, Hung O, Mezei M, Stewart R. Absorption of liposome-encapsulated tetracaine versus nonliposome-encapsulated tetracaine from open wounds in rabbits. Am J Emerg Med. 1994;12:521-523. DOI
26. Mezei M. Biodisposition of liposome encapsulated active ingredients applied to the skin. In: Braun-Falco O, Korting HC, Mailbach HI, eds. Liposome Dermatics. Berlin, Germany: Springer-Verlag; 1992:117-127.
27. Mezei M. Liposomes as penetration promoters and localizers of topically applied drugs. In: Hsieh D, ed. Drug Permeation Enhancement: Theory and Applications. New York, NY, Marcel Dekker Inc; 1994:171-198.